Sort publications on year
-
Pharmaco-Economics
Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.
CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M
Joint Bone Spine ; 2019;86(1);69-75
-
Pharmaco-Economics
Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)
BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.
J Med Econ ; 2018; 21(12):1213-1220
-
Pharmaco-Economics
Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries
LAURENDEAU C, LAFUMA A, BERDEAUX G
J Med Economics ; 12(3):230-237
-
Pharmaco-Economics
Modelling the lifetime economic consequences of glaucoma in France
PHILIPPE NORDMANN J, LAFUMA A, BERDEAUX G
J Med Econ ; 12(1):9-16
-
Pharmaco-Economics
Modelling lifetimes cost consequences of RESTOR for presbyopia in four European countries
LAFUMA A, BERDEAUX G
Eye ; 23(5):1072-80
-
Pharmaco-Economics
Epidemiolgy, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of European countries : literature-and registry-based estimates
TACCONELLI E, SMITH G, HIEKE K, LAFUMA A, BASTIDE P
J Hosp Infect ; 2009;72(2):97-103
-
Pharmaco-Economics
Economics and attitudes regarding spectacles in daily life : a European perspective
Economics and attitudes regarding spectacles in daily life : a European perspective
Ophthalmic Epidemiol ; 16(4):218-223
-
Pharmaco-Economics
Coûts des soins remboursés par l’assurance maladie aux personnes traitées pour diabète : Etudes Entred 2001 et 2007
RICCI P, CHANTRY M, DETOURNAY B, POUTIGNAT N, KUSNIK-JOINVILLE O, RAIMOND V, THAMMAVONG N, WEILL A
Bull Epidemiol Hebd ; 42-43:464-469
-
Pharmaco-Economics
Cost of cataract surgery after implantation of three intraocular lenses
BOUREAU C, LAFUMA A, JEANBAT V, SMITH AF, BERDEAUX G
Clin Ophtalmol ; 3:277-285
-
Pharmaco-Economics
Cost effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma : Analysis Based on the UK General Practitioner Research DataBase
DE NATALE R, LAFUMA A, BERDEAUX G
Clin Drug Investig ; 29(2):111-120
-
Pharmaco-Economics
Bénéfice économique de Pradaxa® en thromboprophylaxie après prothèse totale de hanche ou de genou
BOUÉE S, ZUFFEREY P, FAGNANI F
Thérapie ; 64(4):249-257
-
Pharmaco-Economics
Modelling lifetimes cost consequences of RESTOR in cataract surgery in four European countries
LAFUMA A, BERDEAUX G
BMC Ophtalmol ; 8(1):12
-
Pharmaco-Economics
La prise en charge médicale et chirurgicale de l’obésité : le contexte médico-économique
DETOURNAY B
Technologie&Santé ; (66):19-22
-
Pharmaco-Economics
Etude pharmaco-économique sur la prise en charge du reflux gastro-oesophagien en France en 2005 en médecine générale
MOULY S, CHARLEMAGNE A, LE JEUNNE PH, FAGNANI F
Presse Med ; 37:1397-1406
-
Pharmaco-Economics
Costs and persistence of carbonic anhydrase inhibitor versus alpha2 agonists, associated with beta-blockers, in glaucoma an ocular hypertension : an analysis of the UKGPRD database
LAFUMA A, BERDEAUX G
Curr Med Res Opin ; 24(5):1519-1527
